Hematologic Cancer Clinical Trials

A listing of Hematologic Cancer medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 275 clinical trials
Featured trial
A Phase 2, Single-Arm, Open-Label Study of Itacitinib for the Prevention of Cytokine Release Syndrome Induced by Immune Effector Cell Therapy by Immune Effector Cell Therapy

The purpose of this study is to assess the safety and efficacy of oral administration of itacitinib once daily for the prevention of cytokine release syndrome (CRS) in male or female participants aged 12 years or older and who are planning to receive tisagenlecleucel or axicabtagene ciloleucel immune effector cell …

cancer
hematologic cancer
  • 126 views
  • 10 May, 2022
  • 10 locations
Featured trial
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of the Combination of PI3Kδ Inhibitor Parsaclisib and Ruxolitinib in Participants With Myelofibrosis

To Evaluate the Efficacy and Safety of Parsaclisib and Ruxolitinib in Participants With Myelofibrosis

myeloproliferative syndromes
myelofibrosis
myeloproliferative/myelodysplastic disorders
myeloproliferative disorders
myeloproliferative disorder
  • 0 views
  • 25 Aug, 2021
  • 7 locations
AZD4573 in Novel Combinations With Anti-cancer Agents in Patients With Advanced Blood Cancer

This is a modular, multicentre, open-label, non-randomised, Phase I/II, dose-setting and expansion study including an intra-participants dose ramp up. AZD4573 will be administered intravenously, in novel combinations with anti-cancer agents, to participants with relapsed/refractory (r/r) haematological malignancies.

  • 1 views
  • 12 Jul, 2022
  • 17 locations
Study of BTK Inhibitor LOXO-305 Versus Approved BTK Inhibitor Drugs in Patients With Mantle Cell Lymphoma (MCL) (BRUIN-MCL-321)

This is a study for participants with a type of blood cancer called mantle cell lymphoma (MCL). The main purpose is to compare pirtobrutinib (LOXO-305) to other drugs that work in a similar way

cancer
acalabrutinib
btk inhibitor
measurable disease
neutrophil count
  • 27 views
  • 09 Jul, 2022
  • 159 locations
Real World Evaluation of the Effectiveness of AZD7442 for Prevention of SARS-CoV-2

If a treated cancer patient cannot make antibodies to a Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Emergency Use Authorization (EUA) or approved vaccine, their risk for infection and its sequelae are significantly increased. The Astra-Zeneca Immuno-Suppressed Program (AISP) is designed to address whether a patient treated for cancer who …

  • 0 views
  • 15 Jul, 2022
  • 1 location
A Study of Talquetamab and Teclistamab Each in Combination With a Programmed Cell Death Receptor-1 (PD-1) Inhibitor for the Treatment of Participants With Relapsed or Refractory Multiple Myeloma

The purpose of the study is to identify the safe dose(s) of a PD-1 inhibitor in combination with talquetamab or teclistamab, and to characterize the safety and tolerability of talquetamab or teclistamab when administered in combination with a PD-1 inhibitor.

  • 0 views
  • 24 Jul, 2022
  • 8 locations
Safety and Efficacy of Venetoclax With Escalating Doses of Omacetaxine in Patients With Acute Myeloid Leukemia (VEN-OM)

participants with relapsed/refractory hematologic malignancies including those failing treatment with venetoclax-containing regimens. Treatment plan will consist of an induction phase, followed by a

  • 0 views
  • 25 May, 2022
  • 1 location
A Study of Itacitinib for the Prevention of Cytokine Release Syndrome Induced by Immune Effector Cell Therapy

years or older and who are planning to receive an approved immune effector cell (IEC) therapy for hematologic malignancies.

  • 2 views
  • 06 Jun, 2022
  • 8 locations
Moxetumomab Pasudotox-tdfk (Lumoxiti(TM)) and Either Rituximab (Rituxan(R)) or Ruxience for Relapsed Hairy Cell Leukemia

Background Hairy cell leukemia (HCL) is a rare, slow-growing blood cancer in which the bone marrow makes too many of certain white blood cells. The antibody

  • 1 views
  • 23 Jul, 2022
  • 1 location
Pilot Study of Reduced-Intensity Hematopoietic Stem Cell Transplant of DOCK8 Deficiency

certain types of cancers, including blood cancers. A stem cell transplant is a life-saving treatment for this condition. In this study we are evaluating the efficacy and safety of transplant from

Accepts healthy volunteers
  • 16 views
  • 09 Aug, 2022
  • 1 location